Impax Laboratories, LLC

Delisted

CIK 1003642fmd_194YZCWNHGBME1P9TCT5KS8M3EManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2009 to Mar 31, 2018, 34 periods

Income Statement · Annual · Millions · USD
Line item	FY2009	FY2010	FY2011	FY2012	FY2013	FY2014	FY2015	FY2016	FY2017
Total revenues	358	880	513	582	512	596	860	824	776
Cost of revenue	170	340	255	299	312	281	501	487	535
Gross profit	188	539	258	283	199	313	352	(151)	144
Research and development	63	86	83	81	69	79	71	80	81
Selling, general and administrative	40	53	68	108	120	139	201	202	216
Total operating expenses	118	146	159	200	206	224	283	343	546
Operating income	70	393	100	83	(6)	89	70	(494)	(403)
Interest expense	0	0	0	1	0	0	26	40	53
Interest and investment income	1	1	1	1	1	1	1	1	–
Other non-operating income (expense)	0	(0)	(2)	(0)	152	0	0	(2)	(7)
Income before taxes	71	394	98	83	147	91	59	(576)	(451)
Income tax expense	21	144	33	27	46	33	20	(104)	18
Net income from continuing operations	50	250	65	56	101	57	39	(472)	(469)
Net income	50	250	65	56	101	57	39	(472)	(469)
Net income to common shareholders	–	–	–	–	–	57	39	(472)	(469)